Could Ozempic Be Causing Gastroparesis? Key Warning Signs

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Wellness to Targeted Risk Awareness

If you're taking Ozempic and experiencing persistent nausea, vomiting, or feeling full quickly after small meals, you may be concerned about gastroparesis. Decades of pharmacovigilance have established that delayed gastric emptying can occur with certain medications, and recent reports have raised questions about GLP-1 agonists like Ozempic. This page explains the potential link, the warning signs to watch for, and what the current research says.

Understanding Ozempic and Its Mechanism of Action

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in those with established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism involves slowing gastric emptying, which contributes to glycemic control but also raises concerns about gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation of gastroparesis overlaps significantly with common gastrointestinal adverse effects reported in Ozempic trials. In placebo-controlled studies, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Evidence Linking Ozempic to Gastroparesis

Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can mimic or exacerbate gastroparesis. While transient slowing is intended for glycemic control, persistent or severe delay may lead to gastroparesis-like symptoms. The reported adverse events—nausea, vomiting, dyspepsia, and gastroesophageal reflux disease—are consistent with impaired gastric motility. However, the label does not explicitly list gastroparesis as a distinct adverse reaction, instead grouping these under gastrointestinal adverse reactions. This raises questions about the adequacy of warnings regarding Ozempic and gastroparesis. The label notes that Ozempic has not been studied in patients with a history of pancreatitis and recommends considering other therapies in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but no similar precaution exists for gastroparesis or severe gastric motility disorders. For affected patients, causation considerations involve the timeline between exposure and documented harm. Gastrointestinal adverse reactions, including nausea and vomiting, typically occur during dose escalation, suggesting a temporal relationship. However, distinguishing between transient drug effects and true gastroparesis requires clinical evaluation, including gastric emptying studies. Patients with pre-existing gastroparesis or those taking other medications that slow gastric motility may be at higher risk. The label does not provide specific guidance on monitoring for gastroparesis, nor does it recommend dose adjustments or discontinuation criteria beyond general gastrointestinal tolerability. Risk assessment for patients includes the potential for underdiagnosis of gastroparesis, as symptoms may be attributed to common side effects. The discontinuation rates due to gastrointestinal adverse reactions (3.1% for 0.5 mg and 3.8% for 1 mg) indicate that a subset of patients experiences intolerable symptoms, which could reflect gastroparesis. The absence of explicit gastroparesis warnings may delay appropriate management, such as dose reduction, switching to alternative therapies, or further diagnostic workup. In summary, while Ozempic's label documents a high incidence of gastrointestinal adverse reactions consistent with gastroparesis, it does not specifically warn about this condition. The mechanistic link through delayed gastric emptying supports a plausible association, and the temporal pattern during dose escalation aligns with drug-induced effects. For patients, awareness of these risks and proactive communication with healthcare providers about persistent or severe gastrointestinal symptoms is essential. Further research is needed to clarify the incidence of confirmed gastroparesis in Ozempic users and to optimize risk mitigation strategies. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can mimic or exacerbate gastroparesis—a condition of delayed gastric emptying. Clinical trials show high rates of gastrointestinal adverse reactions like nausea, vomiting, and dyspepsia, which are consistent with gastroparesis symptoms. However, the drug label does not explicitly warn about gastroparesis, raising concerns about underdiagnosis.

Should I stop taking Ozempic if I have gastrointestinal symptoms?

If you experience persistent or severe gastrointestinal symptoms such as nausea, vomiting, or abdominal pain while taking Ozempic, consult your healthcare provider. They may evaluate for gastroparesis using gastric emptying studies and consider dose adjustment or alternative therapies. Do not stop medication without medical advice.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.